

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 273 587 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:

08.01.2003 Bulletin 2003/02

(51) Int Cl.⁷: **C07D 501/04**, C07D 501/22

(21) Application number: 01919924.9

(86) International application number:
PCT/JP01/03182

(22) Date of filing: 13.04.2001

(87) International publication number:
WO 01/079211 (25.10.2001 Gazette 2001/43)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: 13.04.2000 JP 2000111448

(71) Applicant: OTSUKA KAGAKU KABUSHIKI
KAISHA

Osaka-shi, Osaka-fu 540-0021 (JP)


(72) Inventors:

- KAMEYAMA, Yutaka, c/o OTSUKA KAGAKU K.K.
Tokushima-shi, Tokushima 771-0193 (JP)
- FUKAE, Kazuhiro, c/o OTSUKA KAGAKU K.K.
Tokushima-shi, Tokushima 771-0193 (JP)


(74) Representative: Barz, Peter, Dr.
Patentanwalt
Kaiserplatz 2
80803 München (DE)

(54) **PROCESS FOR THE PREPARATION OF A 3-VINYLCEPHEM COMPOUND**

(57) A process for preparing 3-vinyl-cephem compound of the formula (2), the process comprising the step of treating protected 3-vinyl-cephem derivative of the formula (1) in an organic solvent in the presence of perhalogenated acid and an organic protonic acid



wherein each of R¹, R² and R³ is a hydrogen atom or arylmethyl group optionally having a substituent, provided that R¹, R² and R³ can not be a hydrogen atom at the same time.



EP 1 273 587 A1

Description

TECHNICAL FIELD

- 5 [0001] The present invention relates to a process for preparing a cefdinir compound which is widely used as an antibiotic for oral application.

BACKGROUND ART

- 10 [0002] The cefdinir compound is mostly prepared in the form wherein at least one of amino, oxime hydroxyl and carboxyl groups is protected. In the process for preparing the compound, a reaction for removing the protection is carried out in the final step, giving (6R, 7R)-3-vinyl-8-oxo-7 β -(z)-2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamide]-1-aza-5-thiabicyclo[4,2,0]octane-2-carboxylic acid (cefdinir). However, a decisive method has not been established for deprotection of cefdinir compound having various functional groups in the molecule. For example, JP-B-1-49273 discloses a reaction for deprotection of a compound of the formula (1) wherein R¹=R²=H, R³=CHPh₂ in anisole/acetic acid in the presence of etherate of boron trifluoride. The disclosed method can not be industrially utilized since it produces the contemplated compound in a low yield of 35% and requires a large amount of a boron trifluoride compound which is hazardous. JP-A-62-294687 describes a method for deprotection of cephem antibiotics which is extensively conducted, more specifically, a deprotection method using trifluoroacetic acid in the presence of anisole. The method, however, requires a large amount of trifluoroacetic acid which is difficult to industrially use for the reason that the acid is volatile, cumbersome to handle and expensive. In addition, the yield is as low as 28%. Therefore, the method is far from industrially proper.


- 20 [0003] Methods are known for deprotection of protected group of carboxylic acid although not for preparing cefdinir. These methods include a method using 99% formic acid as a solvent [Chem. Pharm. Bull., 30, 4545 (1982)], a method wherein carboxylic acid ester is reacted with aluminum chloride in the presence of anisole [Tetrahedron Lett., 2793 (1979)], and a method using phenols [J. Org. Chem., 56, 3633 (1991)]. The method using formic acid needs expensive 99% formic acid as a solvent in an excessively large amount and gives a carboxylic compound in a very low yield since β -lactam derivative which is instable to an acid decomposes in the procedure for recovery and reuse. The method using aluminum chloride in the presence of anisole is not applicable to the preparation of cefdinir because of high acidity of aluminum chloride. The method using phenols is unable to carry out a reaction in a manner to result in a high yield because cefdinir is instable under highly acidic conditions as is the case with use of formic acid or trifluoroacetic acid in a large amount. All of these reactions eventually give cefdinir wherein the oxime group is made into hydroxyl group so that sin/anti isomerization proceeds in a large amount of protonic acid and strong Lewis acid, resulting in increase of improper impurities. Thus these deprotection methods can not be employed.

- 30 [0004] It has been very difficult heretofore, as described above, to prepare the contemplated cefdinir compound with a high selectivity in a high yield since the deprotection reaction is conducted by usual acid hydrolysis in a β -lactam compound. Thus, it is desired to develop an industrially inexpensive and efficient deprotection method.


- 35 [0005] An object of the present invention is to provide a novel technique capable of efficiently preparing 3-vinyl-cephem compound of the formula (2) from a protected 3-vinyl-cephem derivative of the formula (1) without use of an expensive reagent.

DISCLOSURE OF THE INVENTION

- 40 [0006] The present invention provides a process for preparing 3-vinyl-cephem compound of the formula (2), the process comprising the step of treating a protected 3-vinyl-cephem derivative of the formula (1) in an organic solvent in the presence of perhalogenated acid and an organic protonic acid



wherein each of R¹, R² and R³ is a hydrogen atom or arylmethyl group optionally having a substituent, provided that R¹, R² and R³ can not be a hydrogen atom at the same time.



[0007] In the present invention, hydrogen bonding of an organic protonic acid is conducted in an organic solvent, the acid being weak against an amide group and amino group in the skeleton of the raw material, and only a required amount of strong perhalogenated acid is used in order to efficiently bring about a reaction for deprotection of cefdinir compound which is instable to an acid. Thereby it becomes possible to prepare a highly stable cefdinir compound with high efficiency. The cefdinir compound can stably exist in the reaction system because the reaction employs only a required minimum amount of strong perhalogenated acid which can contribute to the reaction. This process has another feature. Since the reaction need not use a large amount of acid, the desired compound can be isolated from the reaction product by merely extracting the compound dissolved in the organic solvent using a required amount of a base corresponding to the amount of the acid used. Thus a process capable of preparing the contemplated compound industrially easily and inexpensively has been successfully established according to the invention.

[0008] Examples of the arylmethyl group optionally having a substituent which group is represented by R¹, R² and R³, respectively are benzyl, diphenylmethyl, trityl, anisylmethyl and naphthylmethyl which may have a substituent. Examples of the substituent are hydroxy, methyl, ethyl, tert-butyl and like lower alkyl groups having 1 to 4 carbon atoms, and methoxy, ethoxy and like lower alkoxy groups having 1 to 4 carbon atoms. The diphenylmethyl includes the groups of the type wherein a substituted or unsubstituted phenyl group is bonded in the molecule via methylene chain or hetero atom. Specific examples of diphenylmethyl groups are benzyl, p-methoxybenzyl, diphenylmethyl, trityl, 3,4,5-trimethoxybenzyl, 3,5-dimethoxy-4-hydroxybenzyl, 2,4,6-trimethylbenzyl and ditolylmethyl.

[0009] Examples of organic protonic acids which can be used in the invention include preferably those having pK_a of 3 to 5 such as formic acid, acetic acid, chloroacetic acid, propionic acid, 2-ethylhexanoic acid and like substituted or unsubstituted lower alkylcarboxylic acid, benzoic acid, toluic acid and like substituted or unsubstituted aromatic carboxylic acids which can be widely used.

[0010] The amount of the organic protonic acid used is 1 to 20 mole equivalents, preferably 2.5 to 10 mole equivalents and more preferably 3 to 5 mole equivalents, per mole equivalent of the compound of the formula (1).

[0011] Examples of the perhalogenated acid are perchloric acid, periodic acid and perbromic acid. The amount of the perhalogenated acid used is equal to a catalytic amount, and is preferably 0.1 to 5 mole equivalents per mole equivalent of the compound of the formula (1).

[0012] As to the concentration of the perhalogenated acid, 60% perhalogenated acid which is commercially available can be used as it is. Perhalogenated acid is usable when diluted to 10 to 50% with the reaction system.

[0013] Examples of the organic solvent which can be used in the invention are methyl formate, ethyl formate, propyl formate, butyl formate, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, methyl propionate, ethyl propionate and like lower alkyl esters of lower carboxylic acids, acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, methyl isobutyl ketone, diethyl ketone and like ketones, acetonitrile, propionitrile, butyronitrile, isobutyronitrile, valeronitrile and like nitriles, benzene, toluene, xylene, chlorobenzene, anisole and like substituted or unsubstituted aromatic hydrocarbons, dichloromethane, chloroform, dichloroethane, trichloroethane, dibromoethane, propylenedichloride, carbon tetrachloride and like hydrocarbon halides, pentane, hexane, heptane, octane and aliphatic hydrocarbons, cyclopentane, cyclohexane, cycloheptane, cyclooctane and like cycloalkanes. Preferred solvents are benzene, toluene, xylene, dichloromethane, chloroform and dichloroethane. These organic solvents can be used either alone or in combination. These solvents may contain water when so required. The solvents may be used in an amount of about 2 to about 200 liters, preferably about 3 to about 100 liters, per kilogram of the compound of the formula (1). The reaction may be conducted at a temperature of -20 to 100°C, preferably 0 to 50°C.

[0014] The compound of the formula (2) can be obtained as a substantially pure product by usual extraction or crystallization after completion of reaction, and of course, can be purified by other methods.

BEST MODE OF CARRYING OUT THE INVENTION

[0015] The present invention will be described in more detail with reference to the following examples to which the

invention, however, is not limited.

Example 1

[0016] Dissolved in 10 ml of methylene chloride was 1 g of a compound (1a), namely the compound of the formula (1) wherein R¹ is a hydrogen atom, R² is a trityl group and R³ is a hydrogen atom. To the solution were added 0.18 ml (3 equivalents) of 98% (w/w) formic acid, and 0.16 ml (1.6 equivalents) of 60% (w/w) of perchloric acid. Then the mixture was reacted at 30°C for 1 hour. To the reaction mixture was added 7 ml of a saturated aqueous solution of sodium bicarbonate to extract the desired product. 2N hydrochloric acid was added to the obtained aqueous layer to adjust a pH to 3.0. The mixture was cooled to 0 to 3°C. One hour later, the precipitated crystals were subjected to suction filtration and dried under reduced pressure, giving 0.59 g (yield 95%) of the contemplated cefdinir compound of the formula (2).

¹H NMR (DMSO-d₆) 3.32(s, 1H), 3.53(d, J=18Hz, 1H), 3.81(d, J=18Hz, 1H), 5.16(d, J=4.8Hz, 1H), 5.29(d, J=11.7Hz, 1H), 5.56(d, J=17.1Hz, 1H), 5.76(dd, J=4.8, 8.1Hz, 1H), 6.64(s, 1H), 6.89(dd, J=11.7, 17.1Hz, 1H), 7.11(s, 2H), 9.47(d, J=8.1Hz, 1H). 11.3(s, 1H).

Example 2

[0017] A reaction was carried out in the same manner as in Example 1 using 2 dimethylacetamide-coordination crystals of p-toluene sulfonate of compound (1a), whereby a cefdinir compound of the formula (2) was produced in a yield of 96%. The ¹H NMR data of the obtained cefdinir compound were identical with those of the compound produced in Example 1.

Examples 3 to 8

[0018] The same reaction as in Example 1 was conducted with the exception of using different solvents and adjusting the reaction time according to the solvent used. The results of the reaction are shown in Table 1.

Table 1

Example	organic solvent	reaction time(hr)	yield (%)
3	chloroform	1	95
4	benzene	1	94
5	toluene	1	94
6	xylene	1	92
7	ethyl acetate	4	90
8	butyl acetate	4	89

Examples 9 to 12

[0019] The same reaction as in Example 1 was conducted with the exception of using perchloric acid in different concentrations and adjusting the reaction time. The results of the reaction are shown in Table 2.

Table 2

Example	concentration of perchloric acid (%)	reaction time (hr)	yield (%)
9	45	1	96
10	30	1	95
11	20	1.5	92
12	10	6	87

Examples 13 to 16

[0020] The same reaction as in Example 1 was conducted with the exception of using acids shown in Table 3 instead of protonic acid. The results are shown in Table 3.

Table 3

Example	protonic acid	yield (%)
13	acetic acid	95
14	propionic acid	93
15	2-ethylhexanoic acid	86
16	benzoic acid	89

Example 17

[0021] The same reaction as in Example 1 was conducted with the exception of using a compound of the formula (1b) wherein R¹ is a trityl group, R² is a trityl group and R³ is a hydrogen atom in place of the compound (1a), whereby cefdinir compound of the formula (2) was produced in a yield of 91%. The ¹H NMR data of the obtained cefdinir compound were identical with those of the compound produced in Example 1.

Example 18

[0022] The same reaction as in Example 1 was conducted with the exception of using a compound of the formula (1c) wherein R¹ is a hydrogen atom, R² is a trityl group and R³ is a p-methoxybenzyl group in place of the compound (1a), whereby a cefdinir compound of the formula (2) was produced in a yield of 92%. The ¹H NMR data of the obtained cefdinir compound were identical with those of the compound produced in Example 1.

Example 19

[0023] The same reaction as in Example 1 was conducted with the exception of using a compound of the formula (1d) wherein R¹ is a hydrogen atom, R² is a trityl group and R³ is a diphenylmethyl group in place of the compound (1a), whereby a cefdinir compound of the formula (2) was produced in a yield of 94%. The ¹H NMR data of the obtained cefdinir compound were identical with those of the compound produced in Example 1.

Example 20

[0024] The same reaction as in Example 1 was conducted with the exception of using a compound of the formula (1e) wherein R¹ is a trityl group, R² is a trityl group and R³ is a p-methoxybenzyl group in place of the compound (1a), whereby a cefdinir compound of the formula (2) was produced in a yield of 89%. The ¹H NMR data of the obtained cefdinir compound were identical with those of the compound produced in Example 1.

Example 21

[0025] The same reaction as in Example 1 was conducted with the exception of using a compound of the formula (1f) wherein R¹ is a trityl group, R² is a trityl group and R³ is a diphenylmethyl group in place of the compound (1a), whereby a cefdinir compound of the formula (2) was produced in a yield of 91%. The ¹H NMR data of the obtained cefdinir compound were identical with those of the compound produced in Example 1.


INDUSTRIAL APPLICABILITY

[0026] According to the present invention, a cefdinir compound which is instable to an acid can be prepared with a high purity in a high yield by carrying out in an organic solvent a sophisticated combination of hydrogen bonding with a weak acid and deprotection with a strong acid, using a combination of an organic protonic acid in an amount required for hydrogen bonding and a small amount of perhalogenated acid. The present invention can provide a process for preparing a cefdinir compound with industrially extreme ease wherein post-treatment can be simply performed due to a minimum amount of an acid used.

Claims


1. A process for preparing 3-vinyl-cephem compound of the formula (2), the process comprising the step of treating

protected 3-vinyl-cephem derivative of the formula (1) in an organic solvent in the presence of perhalogenated acid and an organic protonic acid



15

wherein each of R^1 , R^2 and R^3 is a hydrogen atom or arylmethyl group optionally having a substituent, provided that R^1 , R^2 and R^3 can not be a hydrogen atom at the same time.



- 30
3. The process according to claim 2, wherein the amount of the organic protonic acid used is 1 to 20 mole equivalents per mole equivalent of the compound of the formula (1), and the amount of the perhalogenated acid used is 0.1 to 5 mole equivalents per mole equivalent of the compound of the formula (1).
- 35
4. The process according to claim 1, wherein the organic protonic acid is that having pKa of 3 to 5.
5. The process according to claim 4, wherein the organic protonic acid is formic acid, acetic acid, chloroacetic acid, propionic acid, 2-ethylhexanoic acid, benzoic acid or toluic acid.
- 40
6. The process according to claim 1, wherein the perhalogenated acid is perchloric acid, periodic acid or perbromic acid.
- 45
7. The process according to claim 1, wherein the arylmethyl group optionally having a substituent is benzyl, diphenylmethyl, trityl, anisylmethyl or naphthylmethyl.
8. The process according to claim 7, wherein the substituent is hydroxy, a lower alkyl group having 1 to 4 carbon atoms or a lower alkoxy group having 1 to 4 carbon atoms.
- 50
9. The process according to claim 7, wherein the arylmethyl group optionally having a substituent is benzyl, p-methoxybenzyl, diphenylmethyl, trityl, 3,4,5-trimethoxybenzyl, 3,5-dimethoxy-4-hydroxybenzyl, 2,4,6-trimethylbenzyl, ditolylmethyl, anisylmethyl or naphthylmethyl.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/03182

A. CLASSIFICATION OF SUBJECT MATTER
Int.Cl⁷ C07D501/04, C07D501/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
Int.Cl⁷ C07D501/00-62

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS (STN), REGISTRY (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 105459 A2 (Fujisawa Pharmaceutical Co., Ltd.), 18 April, 1984 (18.04.84), & BE 897864 A1 & ZA 8306918 A & DK 8304270 A & AU 8319277 A1 & FI 8303370 A & GB 2127812 A1 & AT 8303427 A & CH 657857 A & NO 8303531 A & FR 2533926 A1 & ES 526091 A1 & CA 1206956 A1 & JP 59-89689 A & JP 59-89690 A & JP 62-294687 A & US 4559334 A & ES 543013 A1 & AT 8503554 A	1-9
A	WO 96/26943 A1 (F.HOFFMANN-LA ROCHE AG), 06 September, 1996 (06.09.96), especially, see pages 10-12 & EP 812323 A1 & US 5925632 A & JP 11-501017 A & AU 4877196 A & CA 2212345 A & FI 973500 A & BR 9607046 A & CN 1176641 A	1-9

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
12 July, 2001 (12.07.01)

Date of mailing of the international search report
24 July, 2001 (24.07.01)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.